



Panther Fusion® GBS Assay:

Study shows faster turnaround time, less hands-on time, higher throughput than BD MAX™ GBS assay¹

Caring for Our Most Vulnerable Patients with Confidence



GBS is the **leading cause of serious newborn infections**, and can be transmitted from mothers during delivery.²



Culture-based screening methods are slow and have been found to be **less sensitive** compared to NAATs (nucleic acid amplification tests).³



GBS detection through NAATs has the potential to **save newborn lives** through improved screening accuracy, allowing pregnant patients who are colonized to receive antibiotics.³

Study Design¹

Researchers compared the workflow characteristics and assay performance of the Panther Fusion® GBS assay and the BD MAX™ GBS assay, two FDA-cleared NAATs for GBS detection.


The assays were evaluated using 510 prepartum vaginal-rectal swabs with a 18 to 24 hour Lim broth enrichment. Workflow was evaluated based on a run size of 60 specimens/day.

Results¹

Compared to the BD MAX™ GBS assay, the Panther Fusion® GBS assay demonstrated:

Invalid rates were 1.2% for BD MAX™ (6/510) and 0% for Panther Fusion® (0/510)

GBS Test Results Total (510)		True Positive	True Negative
Panther Fusion®	Positive	124	0
	Negative	0	386
BD MAX™	Positive	120	4
	Negative	1	385



Superior workflow

Shorter total turnaround time for all sample results, less preparation time and hands-on time with fewer return visits to the instrument.



Better analytical sensitivity

100% detection at the 1000 CFU/mL dilution for GBS serotype III, and 100% detection at the 300 CFU/mL dilution for GBS serotype V (vs. 80% and 70% for BD MAX™, respectively).



Strong clinical performance

Comparable clinical performance to the BD MAX™ GBS assay.

Conclusions¹

The Panther Fusion® GBS assay exhibited **superior workflow** to the BD MAX™ in almost every respect, with additional workflow gains as sample numbers increase.

The Panther Fusion® GBS assay also demonstrated comparable clinical performance to the BD MAX™ GBS assay, with a **slightly lower limit of detection**.

Panther Fusion® system decreased labor time is achieved with less hands-on time and preparation time which can amount to \$21,699/year.

- Average of 16,000 samples/year
- Estimated cost of \$40/hour for a medical technologist

This study was supported by Hologic, Inc.

1. Berry GJ, et al. Comparison of the Panther Fusion and BD MAX GBS Assays for Detection of Group B Streptococcus in Prenatal Screening Specimens. J Clin Microbiol. 2019; JCM.01034-19. 2. Cedars-Sinai. Group B Streptococcus Infection in Babies. Cedars-Sinai.org website. Accessed April 21, 2024. <https://www.cedars-sinai.org/health-library/diseases-and-conditions---pediatrics/g/group-b-streptococcus-infection-in-newborns.html>. 3. Shin JH and Pride DT. Comparison of Three Nucleic Acid Amplification Tests (NAATs) and Culture for Detection of Group B Streptococcus (GBS) from Enrichment Broth. J Clin Microbiology. 2019;57(6):e01958-18. doi:10.1128/JCM.01958-18

All trademarks, registered trademarks, and product names are the property of their respective owners.

MISC-06252-001 Rev 002 © 2024 Hologic, Inc. All rights reserved. Hologic, Panther Fusion and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. This information is intended for medical professionals in the U.S. and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to diagnostic.solutions@hologic.com.